Trung Xuan Nguyen1, Monica Abdelmalak2, Christophe Marchand2, Keli Agama2, Yves Pommier2, Mark Cushman1. 1. †Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, and the Purdue Center for Cancer Research, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States. 2. ‡Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-4255, United States.
Abstract
The structure-activity relationships and hit-to-lead optimization of dual Top1-TDP1 inhibitors in the indenoisoquinoline drug class were investigated. A series of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines were synthesized and evaluated. Several compounds displayed potent dual Top1-TDP1 inhibition. The 9-hydroxy series exhibited potencies and cytotoxicities vs Top1 that surpassed those of camptothecin (CPT), the natural alkaloid that is being used as a standard in the Top1-mediated DNA cleavage assay. One member of this series was a more potent Top1 inhibitor at a concentration of 5 nM and produced a more stable ternary drug-DNA-Top1 cleavage complex than CPT.
The structure-activity relationships and hit-to-lead optimization of dual Top1-n class="Gene">TDP1 inhibitors in the indenoisoquinoline drug class were investigated. A series of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines were synthesized and evaluated. Several compounds displayed potent dual Top1-TDP1 inhibition. The 9-hydroxy series exhibited potencies and cytotoxicities vs Top1 that surpassed those of camptothecin (CPT), the natural alkaloid that is being used as a standard in the Top1-mediated DNA cleavage assay. One member of this series was a more potent Top1 inhibitor at a concentration of 5 nM and produced a more stable ternary drug-DNA-Top1 cleavage complex than CPT.
Authors: Andrew Morrell; Michael S Placzek; Jamin D Steffen; Smitha Antony; Keli Agama; Yves Pommier; Mark Cushman Journal: J Med Chem Date: 2007-04-03 Impact factor: 7.446
Authors: Maris A Cinelli; P V Narasimha Reddy; Peng-Cheng Lv; Jian-Hua Liang; Lian Chen; Keli Agama; Yves Pommier; Richard B van Breemen; Mark Cushman Journal: J Med Chem Date: 2012-12-07 Impact factor: 7.446
Authors: Christophe Marchand; Wendy A Lea; Ajit Jadhav; Thomas S Dexheimer; Christopher P Austin; James Inglese; Yves Pommier; Anton Simeonov Journal: Mol Cancer Ther Date: 2009-01 Impact factor: 6.261
Authors: Daniel Polyak; Ngan Phung; Jian Liu; Robert Barrows; Thomas J Emge; Spencer Knapp Journal: Tetrahedron Lett Date: 2017-08-31 Impact factor: 2.415
Authors: Jung Ho Jun; Vineet Kumar; Thomas S Dexheimer; Iwona Wedlich; Marc C Nicklaus; Yves Pommier; Sanjay V Malhotra Journal: Eur J Pharm Sci Date: 2017-10-13 Impact factor: 4.384
Authors: V P Nikolin; N A Popova; V I Kaledin; O A Luzina; A L Zakharenko; N F Salakhutdinov; O I Lavrik Journal: Clin Exp Metastasis Date: 2021-08-09 Impact factor: 5.150
Authors: Daniel E Beck; P V Narasimha Reddy; Wei Lv; Monica Abdelmalak; Gabrielle S Tender; Sophia Lopez; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman Journal: J Med Chem Date: 2016-04-12 Impact factor: 7.446
Authors: Alun Bermingham; Edmund Price; Christophe Marchand; Adel Chergui; Alena Naumova; Emily L Whitson; Lauren R H Krumpe; Ekaterina I Goncharova; Jason R Evans; Tawnya C McKee; Curtis J Henrich; Yves Pommier; Barry R O'Keefe Journal: SLAS Discov Date: 2017-07-11 Impact factor: 3.341
Authors: Mart Toots; Mart Ustav; Andres Männik; Karl Mumm; Kaido Tämm; Tarmo Tamm; Ene Ustav; Mart Ustav Journal: PLoS Pathog Date: 2017-02-09 Impact factor: 6.823